Streptokinase Loaded Solid Lipid Nanoparticles: Preparation and Charactrization

Thrombolytic therapy for acute myocardial infarction consists of recombinant streptokinase (rSK) or tissue plasminogen activator (tPA) and other similar enzymes. In this study, the potential of solid lipid nanoparticles (SLN) as nano-protein carriers of thrombolytic agents was investigated. SLN formulation for utilization in targeted enzymatic delivery of rSK was prepared using a combined technique. Response surface methodology (RSM) was employed to develop the best formulation and analyze the effect of different parameters on the efficient of the SLN-rSK formulation. The optimum condition of the formulation for SLN-rSK preparation was found to be at lipid concentration 0.5 mg/ml, surfactants ratio of 0.5, rSK concentration 4 mg/ml, hgomogenization time 20 min and speed 20000 rpm. The formulation characterization analyzed by SEM method showed that SLN-rSK formulation has a spiral appearance. The size of formulation was determined with DLS (<60 nm) as well as the entrapment efficiency percentage (EE%) calculated as 67.30 %. The integrity assessment approved via SDS-PAGE, no significant change was observed between streptokinase and SLN-rSK formulation in terms of protein structure. Moreover, potency of SLN-rSK conjugates was statistically greater than streptokinase. It seems that high enzymatic activity of SLN-rSK conjugates can be a favorable way for delivering bioactive macromolecules with SLN. Therefore, the SLN-rSK showed to be non-cytotoxic, effective and stable formulation intended to be used as a non thrombolytic dosage form.